Home » Stocks » Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. (INFI)

Stock Price: $1.17 USD 0.10 (9.35%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 68.88M
Revenue (ttm) 1.44M
Net Income (ttm) -43.16M
Shares Out 58.87M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $1.17
Previous Close $1.07
Change ($) 0.10
Change (%) 9.35%
Day's Open 1.20
Day's Range 1.15 - 1.24
Day's Volume 4,182,716
52-Week Range 0.60 - 1.68

More Stats

Market Cap 68.88M
Enterprise Value 27.52M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 58.87M
Float 39.35M
EPS (basic) -0.75
EPS (diluted) -0.75
FCF / Share -0.70
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 46,726
Short Ratio 0.05
Short % of Float 0.17%
Beta 1.75
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 47.90
PB Ratio 8.03
Revenue 1.44M
Operating Income -41.55M
Net Income -43.16M
Free Cash Flow -40.19M
Net Cash 41.36M
Net Cash / Share 0.70
Gross Margin -2,181.85%
Operating Margin -2,889.71%
Profit Margin -2,999.20%
FCF Margin -2,794.65%
ROA -44.36%
ROE -474.68%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$2.50*
(113.68% upside)
Low
1.00
Current: $1.17
High
3.50
Target: 2.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue3.0522.156.0018.72109165-47.1192.7771.33
Revenue Growth-86.23%269.1%-67.95%-82.83%-33.9%---49.22%30.06%-
Gross Profit3.0522.156.0018.72109165-47.1192.7771.33
Operating Income-45.66-11.93-36.45-30.89-127-7.92-128-52.81-38.53-48.97
Net Income-47.06-11.25-41.83-30.10-128-17.42-127-53.96-40.04-48.98
Shares Outstanding56.9855.4150.5649.6149.0848.5647.9431.7126.6226.32
Earnings Per Share-0.83-0.20-0.83-0.61-2.62-0.36-2.64-1.70-1.50-1.86
Operating Cash Flow-41.53-4.71-36.71-154-83.65118-114-80.14-33.11-26.59
Capital Expenditures-2.33-0.711.48-6.43-1.36-1.75-1.30-1.54-1.95
Free Cash Flow-43.86-4.71-36.00-153-90.08116-116-81.44-34.65-28.53
Cash & Equivalents42.7658.5957.6193.22245334215327116101
Total Debt1.93-6.0019.5920.01---37.55-
Net Cash / Debt40.8358.5951.6173.6322533421532778.85101
Assets49.0160.2259.35126289369231336124125
Liabilities41.297.7611.6243.2019016029.4425.4610975.08
Book Value7.7352.4647.7382.4598.5620920131015.4349.48
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Infinity Pharmaceuticals, Inc.
Country United States
Employees 25
CEO Adelene Q. Perkins

Stock Information

Ticker Symbol INFI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: INFI

Description

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.